<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-6-2-7">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>		
			</div>

			<div class="slide-title red two-line">
				Outcomes in severe aplastic anaemia: <br />evolution over time
			</div>


			<div class="content-container">

				<ul>
					<li><span>Overall survival rates with bone marrow transplantation (BMT) have improved over time</span></li>
					<li><span>The success of BMT is strongly correlated with age and donor type</span></li>
					<li><span>Studies suggest that 5-year survival after matched donor transplantation may be as follows:<sup>1</sup></span>
						<ul>
							<li><span>80–90% in patients aged &lt;20 years</span></li>
							<li><span>50–70% in patients aged 20–40 years</span></li>
							<li><span>~50% in patients aged >40 years</span></li>
						</ul>
					</li>
					<li><span>After unrelated donor (UD) transplantation, survival rates are more variable and may not be as high as those observed after matched donor transplantation (28–94%)<sup>2</sup></span></li>
					<li><span>However, graft-versus-host disease and the risk of transplant rejection still remain major concerns for severe aplastic anaemia patients<sup>3,4</sup></span></li>
					<li><span>Despite improvements in antimicrobial support therapy, 5-year survival rates among patients refractory to IST is still &lt;60%, indicating the need for new, effective treatments for patients who may not be eligible for transplant but are no longer responsive to IST<sup>5</sup></span></li>
				</ul>

			</div>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/GuptaV-2010-Haematologica-v95p2119.pdf"><span>Gupta V <i>et al. Haematologica</i> 2010;95:2119</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/PeinemannF-2009-Haematologica-v94p1732.pdf"><span>Peinemann F <i>et al. Haematologica</i> 2009;94:1732</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/BrodskyRA-2005-Lancet-v365p1647.pdf"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ValdezJM-2011-ClinInfectDis-v52p726.pdf"><span>Valdez JM <i>et al. Clin Infect Dis</i> 2011;52:726</span></li>
			</ol>
		</div>

	</div>
</div>